IGF-1 LR3 (Long R3 IGF-1): structure, IGF-1R signalling, and the limits of the evidence

IGF-1 LR3 (Long R3 IGF-1) is an 83-amino-acid recombinant analogue of human insulin-like growth factor 1 (IGF-1). Two deliberate changes distinguish it from native IGF-1: a glutamate-to-arginine substitution at position 3 of the native sequence (the "R3") and a 13-residue extension added to the N-terminus (the "Long"). Both serve one purpose: to sharply weaken the peptide's binding to the IGF-binding proteins (IGFBPs), so that a far larger fraction stays free and available to the receptor. This monograph summarises the published cell and animal literature: molecular design, IGF-1R signalling, the honest limits of the evidence base, and a documented proliferative concern.

Everything below is a reference synthesis of peer-reviewed literature. IGF-1 LR3 is supplied strictly as a laboratory research reagent (RUO): not for human consumption, not for diagnostic or therapeutic use. No approved human indication exists, and nothing here is a dosing protocol. Regimens are covered separately in the dosing reference and the general reconstitution chart.

Starting point: native IGF-1 and the IGFBP problem

Native human IGF-1 is a single-chain, 70-amino-acid polypeptide, structurally related to proinsulin and the principal mediator of growth hormone's anabolic action. It signals mainly through the type-1 IGF receptor (IGF-1R), a receptor tyrosine kinase ^[4].

The detail that explains why IGF-1 LR3 exists at all: in the bloodstream IGF-1 is almost never free. Most of it is captured by a family of six high-affinity binding proteins (IGFBP-1 through IGFBP-6), chiefly IGFBP-3, which carries IGF-1 in a ternary complex with the acid-labile subunit. These proteins are not passive carriers: they act as a circulating reservoir, prolong the peptide's plasma residence, and sequester the ligand, limiting its access to the receptor ^[3][4].

For the experimenter this creates a practical problem. Add native IGF-1 to a serum-containing culture, or dose an animal with it, and a large (and variable) fraction of the added ligand is immediately intercepted by the IGFBPs present. The effective, receptor-available concentration ends up both lower than nominal and poorly controlled ^[3].

Structure and molecular design: two changes in one molecule

IGF-1 LR3 is native IGF-1 with two independent modifications, each worked out separately. Both exist to pull the peptide away from the binding proteins.

The Glu3 → Arg substitution (the "R3")

In 1988, Bayne and colleagues produced a systematic series of structural analogues of human IGF-1 to determine which regions govern binding to serum binding proteins versus binding to the receptors. The N-terminal region proved decisive: analogues altered there showed markedly reduced affinity for the binding proteins and for the type-2 IGF receptor while retaining IGF-1R binding ^[1]. The glutamate-3-to-arginine substitution (hence "R3") was carried into a practical reagent by Francis and colleagues in 1992 ^[2].

The 13-residue N-terminal extension (the "Long")

The second modification adds a 13-amino-acid extension peptide (MFPAMPLSSLFVN) to the N-terminus. Part of its origin is purely manufacturing: the extension derives from the recombinant fusion-protein expression system used to make the analogue in bacteria, and it improves yield. But it is not merely an artefact of convenience: it further weakens IGFBP association, reinforcing the Arg3 effect ^[2]. Seventy native residues plus the 13-residue extension give the 83-amino-acid chain. Note that "R3" refers to position 3 of the native sequence, not to the third residue of the 83-residue construct.

What the combination achieved

Francis and colleagues compared these analogues directly, and their conclusion is the full rationale for the molecule: the increased biological potency is due chiefly to reduced affinity for the IGF-binding proteins, not to improved receptor binding ^[2]. LR3 IGF-1 does not bind IGF-1R better than native IGF-1. In fact its receptor affinity is slightly lower. It is more potent in biological systems precisely because an incomparably larger fraction stays free.

Why escaping the IGFBPs changes the pharmacology

The consequence is a large shift in the free fraction. In any system containing IGFBPs (a serum-containing medium or a living animal) LR3 IGF-1 behaves as if a much higher concentration of native IGF-1 had been added, because the buffering step that normally absorbs most of the dose barely engages.

The clearest quantitative estimate comes from Tomas and colleagues, who infused IGF-1 and LR3 IGF-1 into young female rats for 14 days via subcutaneous osmotic pumps. Both peptides dose-dependently increased body-weight gain, nitrogen balance, and feed-conversion efficiency, but LR3 IGF-1 was markedly more potent: roughly 44 µg/day of the variant produced effects comparable to 278 µg/day of native IGF-1, an approximately six-fold potency difference ^[8]. These are preclinical figures obtained in rats; they describe what was infused into the animals and cannot be back-calculated into a dose for anything else.

The half-life claim that does not hold up

It is widely repeated that IGF-1 LR3 has a sharply extended half-life (figures of 20–30 hours circulate) and supposedly because it evades the binding proteins. This inverts the pharmacology. IGFBP binding is precisely what prolongs IGF-1's plasma residence: the bound pool is a reservoir that protects the peptide from clearance. Remove the binding and you remove the reservoir. Ballard and colleagues compared the plasma clearance of labelled IGF-1, IGF-2, and des(1-3)IGF-1 in rats; des(1-3)IGF-1, which shares LR3's very weak IGFBP binding, was cleared markedly faster than intact IGF-1 (mean total plasma clearance 4.59 versus 1.20 mL/min per kg) ^[5]. That was measured on des(1-3)IGF-1, not on LR3, so this is an argument by analogy; but the direction is mechanistically clear, and the circulating "long" figures for LR3 trace back to no clean primary source.

IGF-1 LR3 versus native IGF-1 versus des(1-3)IGF-1

These three are constantly confused, though they are different molecules with different behaviour:

• Native IGF-1: 70 residues, unmodified; binds IGFBPs with high affinity, so most is sequestered, the free fraction is small, and actual activity depends heavily on the system's IGFBP profile ^[3].
• des(1-3)IGF-1: a truncated analogue, 67 residues, made by removing the N-terminal tripeptide. It achieves weak IGFBP binding by subtraction; it retains IGF-1R affinity and is cleared faster from plasma ^[5].
• IGF-1 LR3: an extended and substituted analogue, 83 residues; it achieves weak binding through two combined changes, and the N-terminal extension additionally suits recombinant production ^[2].

The common thread is that des(1-3)IGF-1 and LR3 IGF-1 are two different engineering routes to the same goal: an IGF-1 that the binding proteins largely ignore.

Signalling: IGF-1R, PI3K/Akt, and MAPK

Once free, IGF-1 LR3 does what IGF-1 does: it engages IGF-1R. Ligand binding activates the receptor's intrinsic tyrosine kinase, which autophosphorylates and recruits IRS-family and Shc adaptor proteins, after which the signal splits into two main arms ^[6]:

• IRS → PI3K → Akt: the metabolic and cell-survival arm, extending downstream to mTOR, GSK3, and FoxO transcription factors; it drives protein synthesis, glucose uptake, and suppression of apoptosis.
• Shc → Ras → Raf → MEK → ERK (MAPK): the mitogenic arm, tied to proliferation and cell-cycle entry.

Which arm dominates depends on cell type and context. In cultured skeletal myotubes, Rommel and colleagues showed that IGF-1-induced hypertrophy is mediated specifically by PI3K/Akt/mTOR and PI3K/Akt/GSK3 signalling ^[7]: the hypertrophic read-out follows the Akt branch. IGF-1R signalling also cross-talks with the insulin receptor, given the close homology of the two receptors.

What IGF-1 LR3 is actually used for: the preclinical record

Cell culture: the best-documented application

The best-documented real-world use of Long R3 IGF-1 is not in vivo but as a cell-culture supplement: a more potent, more stable insulin substitute in serum-free industrial cultures. Morris and Schmid studied exactly this, showing the effects of insulin and LongR3 on serum-free Chinese hamster ovary (CHO) cell cultures expressing recombinant proteins ^[9]. Because serum-free media contain no IGFBPs, and LR3 is active at far lower concentrations than insulin, it sustains proliferation and productivity in bioreactor culture. This is the application the molecule was actually productised for.

Rodent models of anabolism and metabolism

Outside culture, LR3 IGF-1 appears in the preclinical literature as a tool for studying the IGF axis where IGFBP interference would distort the read-out: anabolic and nitrogen-balance studies in rodents ^[8], plus models probing IGF-1R-dependent proliferation. The analogue's value here is methodological: it separates receptor-level effects from binding-protein effects, which native IGF-1 cannot.

Proliferation and the oncological concern

This is the section that defines which category the molecule belongs to, and it follows directly from the mechanism described above rather than being a disclaimer tacked on at the end. IGF-1R signalling is mitogenic and anti-apoptotic, not a side effect, but the pathway working as designed. The same PI3K/Akt and Ras/MAPK arms that drive protein synthesis and cell survival are among the most thoroughly documented pro-tumorigenic routes in cancer biology. Pollak's review lays this out in detail: IGF-1R activation supports proliferation, protects transformed cells from apoptosis, and promotes tumour progression, which is exactly why IGF-1R was pursued as an oncology target to be blocked, not stimulated ^[10].

The epidemiology points the same way. The systematic review and meta-regression by Renehan and colleagues found that higher circulating IGF-1 concentrations were associated with increased risk of certain cancers, notably prostate and premenopausal breast cancer ^[11]. This is an association in observational data within the physiological range. It does not establish causation, but it is consistent with the mechanistic concern rather than refuting it.

Combine two facts: IGF-1 LR3 is engineered to defeat the very mechanism by which the body controls how much free IGF-1 reaches the receptor, and it is roughly six-fold more potent than native IGF-1 in vivo ^[8]. A compound whose entire design premise is sustained, unbuffered stimulation of a well-characterised proliferative and anti-apoptotic receptor carries an unquantified proliferative risk, including the possibility of promoting the growth of already-present, undetected neoplastic cells. No study has characterised this risk in humans.

Limits of the evidence base: preclinical versus human

An honest list of what is not known here is longer than most sources admit:

• The evidence base is mostly rodents and cell culture. The formative in vivo data on LR3 IGF-1 are early-1990s rat studies ^[8] with groups small by modern standards. Rodent IGF and IGFBP physiology is not identical to human.
• There are no controlled human trials of IGF-1 LR3. Not "few": none of any weight. Any claim about its behaviour in the human body is a cross-species extrapolation.
• No approved indication exists anywhere. Recombinant native IGF-1 (mecasermin) has a narrow approved use in severe primary IGF-1 deficiency; that approval says nothing about LR3, a different molecule with deliberately different binding behaviour.
• The pharmacokinetics are poorly characterised. The circulating half-life figures trace back to no clean primary source, and the nearest direct measurement was made on a related but distinct analogue ^[5].
• There are no long-term safety data in any species at a relevant exposure, and the proliferative concern above is exactly the kind of risk that only long-term data could close.

Handling and characterisation

IGF-1 LR3 is supplied as a lyophilised powder, how peptides of this size are stabilised for storage and shipping. As a recombinant protein it is conformationally more fragile than a short synthetic peptide: sensitive to heat, to repeated freeze-thaw cycles, and to vigorous agitation, each of which can denature or aggregate it and silently strip activity. For in vitro work the material is reconstituted in sterile water, PBS, or dilute acetic acid depending on the experiment. General reconstitution principles are covered in the monograph on bacteriostatic water. Because identity and purity are variable for this class, batch-level analytics matter more than the label: the product page carries the specification and a batch certificate of analysis.

Research use only

This monograph is assembled from publicly available peer-reviewed literature and is provided for reference purposes only. It is not medical advice and not a recommendation for use. IGF-1 LR3 is an experimental compound that is not an approved medicine in any jurisdiction. The products referenced here are supplied strictly for laboratory research purposes only: not for human consumption, and not for diagnostic or therapeutic use. All quantities and findings above were obtained under controlled experimental conditions in cells or animals and cannot be read as instructions.